Prostanoids and Blood Pressure: Which Way is Up?

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2004 Sep 17

PMID 15372097

Citations 14

Authors

Helene Francois

Thomas M Coffman

Affiliations

Soon will be listed here.

Abstract

Members of the family of prostanoids, made up of prostaglandins and thromboxanes, are generated via COX-mediated metabolism of arachidonic acid. These lipid mediators exhibit wide-ranging biological actions that include regulating both vasomotor tone and renal sodium excretion. As COX inhibition is often associated with sodium retention leading to edema and hypertension, prostanoids appear to have a role in preventing the development of high blood pressure. On the other hand, prostaglandin E2 (PGE2) and PGI2 have also been implicated as determinants of renin secretion. A new study suggests that PGI2 plays a critical role in stimulating renin release and promoting hypertension following renal artery stenosis.

Citing Articles

Association between acetaminophen administration and outcomes in critically ill patients with gout and hypertension.

Yi X, Xie B, Hu Y, Gong T, Chen M, Cui X Front Pharmacol. 2024; 15:1445975.

PMID: 39193324 PMC: 11348437. DOI: 10.3389/fphar.2024.1445975.

Cell-Specific Actions of the Prostaglandin E-Prostanoid Receptor 4 Attenuating Hypertension: A Dominant Role for Kidney Epithelial Cells Compared With Macrophages.

Yang T, Song C, Ralph D, Andrews P, Sparks M, Koller B J Am Heart Assoc. 2022; 11(19):e026581.

PMID: 36172956 PMC: 9673718. DOI: 10.1161/JAHA.122.026581.

Novel Evidence-Based Combination of Plant Extracts with Multitarget Mechanisms of Action for the Elimination of Hot Flashes during Menopause.

Tsoumani M, Nikolaou P, Argyropoulou A, Tseti I, Mitakou S, Andreadou I Molecules. 2022; 27(4).

PMID: 35209016 PMC: 8874944. DOI: 10.3390/molecules27041221.

EP3 Receptor Deficiency Improves Vascular Remodeling and Cognitive Impairment in Cerebral Small Vessel Disease.

Liu N, Tang J, Xue Y, Mok V, Zhang M, Ren X Aging Dis. 2022; 13(1):313-328.

PMID: 35111376 PMC: 8782563. DOI: 10.14336/AD.2021.0627.

Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury.

Pan Y, Cao S, Terker A, Tang J, Sasaki K, Wang Y Kidney Int. 2021; 101(1):79-91.

PMID: 34774558 PMC: 8741730. DOI: 10.1016/j.kint.2021.09.033.

References

Gurwitz J, Avorn J, Bohn R, Glynn R, Monane M, Mogun H . Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994; 272(10):781-6. View

Johnson A, Nguyen T, Day R . Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121(4):289-300. DOI: 10.7326/0003-4819-121-4-199408150-00011. View

de Leeuw P . Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs. 1996; 51(2):179-87. DOI: 10.2165/00003495-199651020-00001. View

Carey R, McGrath H, Pentz E, Gomez R, Barrett P . Biomechanical coupling in renin-releasing cells. J Clin Invest. 1997; 100(6):1566-74. PMC: 508338. DOI: 10.1172/JCI119680. View

Jensen B, Kurtz A . Differential regulation of renal cyclooxygenase mRNA by dietary salt intake. Kidney Int. 1997; 52(5):1242-9. DOI: 10.1038/ki.1997.449. View

McAdam B, Mardini I, Kapoor S, Lawson J, FitzGerald G . Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999; 96(1):272-7. PMC: 15129. DOI: 10.1073/pnas.96.1.272. View

Narumiya S, Sugimoto Y, Ushikubi F . Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999; 79(4):1193-226. DOI: 10.1152/physrev.1999.79.4.1193. View

Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A . In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol. 1995; 116(7):2828-37. PMC: 1909220. DOI: 10.1111/j.1476-5381.1995.tb15933.x. View

Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, WHELTON A . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284(10):1247-55. DOI: 10.1001/jama.284.10.1247. View

10.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21):1520-8, 2 p following 1528. DOI: 10.1056/NEJM200011233432103. View

11.

Yang T, Park J, Arend L, Huang Y, Topaloglu R, Pasumarthy A . Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem. 2000; 275(48):37922-9. DOI: 10.1074/jbc.M006218200. View

12.

Harris R, Breyer M . Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol. 2001; 281(1):F1-11. DOI: 10.1152/ajprenal.2001.281.1.F1. View

13.

FitzGerald G, Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001; 345(6):433-42. DOI: 10.1056/NEJM200108093450607. View

14.

Mukherjee D, Nissen S, Topol E . Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286(8):954-9. DOI: 10.1001/jama.286.8.954. View

15.

Frishman W . Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002; 89(6A):18D-25D. DOI: 10.1016/s0002-9149(02)02233-6. View

16.

Cheng Y, Austin S, Rocca B, Koller B, Coffman T, Grosser T . Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296(5567):539-41. DOI: 10.1126/science.1068711. View

17.

Qi Z, Hao C, Langenbach R, Breyer R, Redha R, Morrow J . Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002; 110(1):61-9. PMC: 151026. DOI: 10.1172/JCI14752. View

18.

Ray W, Stein C, Daugherty J, Hall K, Arbogast P, Griffin M . COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002; 360(9339):1071-3. DOI: 10.1016/S0140-6736(02)11131-7. View

19.

Bell P, Lapointe J, Peti-Peterdi J . Macula densa cell signaling. Annu Rev Physiol. 2003; 65:481-500. DOI: 10.1146/annurev.physiol.65.050102.085730. View

20.

Whelton A . COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J Hypertens Suppl. 2003; 20(6):S31-5. View